Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy - PubMed
Review
. 2015 Jul-Aug;58(1):19-31.
doi: 10.1016/j.pcad.2015.04.004. Epub 2015 May 1.
Affiliations
- PMID: 25936907
- DOI: 10.1016/j.pcad.2015.04.004
Review
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy
Lee Joseph et al. Prog Cardiovasc Dis. 2015 Jul-Aug.
Abstract
Low-density lipoprotein cholesterol (LDL-C) reduction with statins is the cornerstone of atherosclerotic cardiovascular disease (CVD) prevention. The LDL-C lowering non-statin therapy ezetimibe also modestly reduces CVD risk when added to statin therapy. There remains a clinical need for additional LDL-C lowering agents to reduce CVD risk in patients with genetic hypercholesterolemia, statin intolerance, or who are at high risk due to clinical CVD or diabetes. In clinical trials, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition using monoclonal antibodies has demonstrated robust LDL-C lowering efficacy of 50-65% and a favorable safety profile. These agents are a promising therapeutic strategy for addressing the unmet needs for additional CVD risk reduction. Regulatory approval for PCSK9 monoclonal antibodies may occur in the near future, and additional agents for PCSK9 inhibition are under development. This review focuses on the mechanism of LDL-C reduction using PCSK9 inhibition, as well as the phase I to III clinical trials of PCSK9 inhibitors. Results of the ongoing phase III CVD outcome trials are eagerly awaited.
Keywords: Hypercholesterolemia; Monoclonal antibodies; Proprotein convertase subtilisin/kexin type 9.
Copyright © 2015 Elsevier Inc. All rights reserved.
Similar articles
-
PCSK9 antibodies: A new class of lipid-lowering drugs.
Gouni-Berthold I. Gouni-Berthold I. Atheroscler Suppl. 2015 May;18:21-7. doi: 10.1016/j.atherosclerosissup.2015.02.003. Atheroscler Suppl. 2015. PMID: 25936300 Review.
-
Sahebkar A, Watts GF. Sahebkar A, et al. Clin Ther. 2013 Aug;35(8):1082-98. doi: 10.1016/j.clinthera.2013.06.019. Epub 2013 Aug 8. Clin Ther. 2013. PMID: 23932550 Review.
-
Yadav K, Sharma M, Ferdinand KC. Yadav K, et al. Nutr Metab Cardiovasc Dis. 2016 Oct;26(10):853-62. doi: 10.1016/j.numecd.2016.05.006. Epub 2016 May 30. Nutr Metab Cardiovasc Dis. 2016. PMID: 27352986 Review.
Cited by
-
Kong L, He Q, Ma D, Shi W, Xin Q, Jiang C, Wu J. Kong L, et al. FEBS Open Bio. 2024 May;14(5):831-842. doi: 10.1002/2211-5463.13797. Epub 2024 Mar 26. FEBS Open Bio. 2024. PMID: 38531630 Free PMC article.
-
PCSK9: A Key Target for the Treatment of Cardiovascular Disease (CVD).
Sobati S, Shakouri A, Edalati M, Mohammadnejad D, Parvan R, Masoumi J, Abdolalizadeh J. Sobati S, et al. Adv Pharm Bull. 2020 Sep;10(4):502-511. doi: 10.34172/apb.2020.062. Epub 2020 Aug 9. Adv Pharm Bull. 2020. PMID: 33062601 Free PMC article. Review.
-
An update on lipid apheresis for familial hypercholesterolemia.
Taylan C, Weber LT. Taylan C, et al. Pediatr Nephrol. 2023 Feb;38(2):371-382. doi: 10.1007/s00467-022-05541-1. Epub 2022 Apr 25. Pediatr Nephrol. 2023. PMID: 35467154 Free PMC article. Review.
-
Finding inhibitors for PCSK9 using computational methods.
Zainab R, Kaleem A, Ponczek MB, Abdullah R, Iqtedar M, Hoessli DC. Zainab R, et al. PLoS One. 2021 Aug 5;16(8):e0255523. doi: 10.1371/journal.pone.0255523. eCollection 2021. PLoS One. 2021. PMID: 34351937 Free PMC article.
-
Geiger R, Fatima N, Schooley JF Jr, Smyth JT, Haigney MC, Flagg TP. Geiger R, et al. Physiol Rep. 2021 Jan;8(24):e14675. doi: 10.14814/phy2.14675. Physiol Rep. 2021. PMID: 33356020 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous